2025 ESMO Immuno-Oncology Awardee, Ignacio Melero, is confident that combinations and novel multispecific agents will result in synergistic strategies to ensure the continued success of cancer immunotherapy
Phase I–II studies showcase the clinical potential of novel ADCs with enhanced targeting and/or payload strategies
Studies underline that a tumour-agnostic approach may help improve treatment options
Impressive results from the Chinese LUMINET-1 phase III study confirm and extend previous findings in Western patients
Recognising diversity is essential to providing effective, well tolerated and accessible cancer care globally
A triple combination investigated in a phase I trial adds to the growing therapeutic options directed at this emerging target
Initial results of a phase II trial with rezatapopt suggest real promise in an area that has eluded druggable targeting
For adolescents and young adults with cancer, individualised care that addresses their unique medical and psychosocial needs is essential to improving outcomes and quality of life
Can artificial intelligence finally unlock the full potential of cancer genomics? Discover how new digital tools are closing the gap between data and clinical action in oncology.
Computational models can overcome current limitations of 3D analysis of tumour samples
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.